Alpha1-adrenergic antagonists and floppy iris syndrome: tip of the iceberg?
Schwinn
Debra A
DA
Afshari
Natalie A
NA
D058668:Adrenergic alpha-1 Receptor Antagonists; D000316:Adrenergic alpha-Agonists / Q000008:administration & dosage; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects*; D017292:Doxazosin / Q000009:adverse effects; D006801:Humans; D007431:Intraoperative Complications; D007499:Iris Diseases / Q000139:chemically induced* / Q000175:diagnosis; D018918:Phacoemulsification; D011224:Prazosin / Q000009:adverse effects / Q000031:analogs & derivatives; D011680:Pupil / Q000187:drug effects; D011799:Quinazolines / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013577:Syndrome; D000077409:Tamsulosin
D058668:Adrenergic alpha-1 Receptor Antagonists; D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D013449:Sulfonamides; C041226:Terazosin; C047638:alfuzosin; D000077409:Tamsulosin; D017292:Doxazosin; D011224:Prazosin